Topic Listing for Teva Pharmaceutical Industries

Accompanying Notes Integral Part Condensed Financial Statements Accompanying Notes Integral Part Financial Statements
Accounting Convertible Debt Instruments Settled Cash Conversion Accounting Principles
Accounting Uncertainty Income Taxes Accounts Payable Accruals
Acquisition Acquisition Barr Pharmaceuticals Inc
Acquisition Bentley Pharmaceuticals Inc Acquisition Bolster Teva`s Biotechnology Capabilities
Acquisition Cogenesys Inc Acquisition Dorom Srl
Acquisition Expected Accretive After Closing Acquisition Ivax Corporation
Acquisition Provide Teva Strong Platform Become Leading Player Acquisition Sicor Inc
Acquisition Units Viventia Biotech Acquisitions
Active Biotech Active Pharmaceutical Ingredient Api Sales
Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients Api
Active Pharmaceutical Ingredients Api Sales Active Pharmaceutical Ingredients Sales Api
Adagio Add New Product Lines Growth Markets
Additional Changes Composition Board Additional Covenants
Additional Definitions Additional Launches Europe Follow
Address Principal Executive Offices Adjusted Results
Adjustment Relating Adrs Adjustments Combined Condensed Pro Forma Statement Income
Adjustments Combined Condensed Pro Forma Statements Income Administration
Administrative Agent Adrs
Ads Fees Adss
Advertising Expenses Affirmative Covenants
Agenda Annual Meeting Include Following Resolutions Agenda Special Meeting Include Following Resolutions
Aggregate Contractual Obligations Agreement Acquire Barr Pharmaceuticals Inc
Agreement Anchen Impax Allegro
Allowance Doubtful Accounts Alternative Cardenereg
Amendment Credit Agreement Amendment Form 6-k
Amendment Termination Stock Purchase Plan Amendments Existing Credit Agreement
Amendments Form Security American Depositary Shares
Amyotrophic Lateral Sclerosis Als Analysis
Animal Health Announced Incoming Officer
Annual Sales Increased Record 118 Annual Sales Increased Record 936
Antares Pharma Wwwantarespharmacom Antares Safe Harbor Statement Private Securities Litigation Reform
Antisense Therapeutics Api
Api Sales Appellate Court Denies Apotex Request Injunctive Relief
Approved Canada Monotherapy Early Adjunct Levodopa Moderate-to-advanced Disease Approved Monotherapy Early Disease Adjunct Therapy Moderate Advanced
Asia Assignment Guarantee
Assumption Astellas
Atl Tv1102 Audit Committee
Audit Committee Financial Expert Autoimmune Diseases Pipeline Lupus
Autoimmune Diseases Pipeline-lupus Average Wholesale Price Awp Litigation
Average Wholesale Price Litigation Azilect
Azilect Rasagiline Mesylate Azilect Reg
Azilect Reg Market Potential Dramatically Increases Drug Become Azilectreg
Balance Sheet Data Banks Books
Barr Barr Patent Litigation Settlements
Barr Pharmaceuticals Inc Forward-looking Statements Basis Presentation
Because Substantial International Operations Sales Lesser Extent Profits Because Substantial International Operations Sales Profits Adversely Affected
Behalf Teva Pharmaceutical Industries Limited Bentley
Bentley Acquisition Bentley`s Safe Harbor Statement Private Securities Litigation Reform
Between Bank Hapoalim Teva Pharmaceuticals Usa Inc Bill Marth Teva North America President Ceo
Biogenerics Biopharmaceutical Operations Biopharmaceutical Operations
Biopharmaceuticals Biogenerics Biosimilar G-csf Product Receive Marketing Authorization
Board Committee Meetings Board Directors Shareholder Ivax Corporation
Board Directors Shareholders Ivax Corporation Board Practices
Board Practices Committees Bravo
Bravo Trial Together Ongoing Allegro Investigate Oral Laquinimod Capital Gains Income Taxes Applicable Non-israeli Shareholders
Capitalization Shares Stockholder Information Cash Equivalents
Cash Flow Cee Countries Members -see Regulation- European Union
Central Eastern Europe Cee Ceo Center Management
Certain Details Relating Defined Benefit Plans Certain Details Relating Pension Plans
Certain One-time Charges Benefits Certain Transactions
Certifications Chairman Board
Change Control Changes Regulatory Environment Prevent Utilizing Exclusivity Periods Important
Changes Senior Management Charges Earnings Resulting Ivax Acquisition Material Adverse Impact
Cladribine Mylinax Clarithromycin
Clinical Material Close Manufacturing Facility Cidra 2006
Closing Closing Barr Acquisition Remains Subject Various Conditions Even
Closing Scheduled 2008 Code Ethics
Cogenesys Cogenesys Acquisition
Cogenesys Inc Commercial Matters
Commitments Commitments Contingencies
Committees Board Community Affairs Committee
Companies Host Webcast Conference Call 0830 Est Comparison 2009 2008
Compensation Compensation Committee
Competition Competition Pricing Regulatory Matters
Components Accumulated Other Comprehensive Income Comprehensive Income
Comprehensive Income Loss Concentration Credit Risks
Concentration Credit Risks-allowance Doubtful Accounts Concerning Holders Debentures
Conditions Conditions Effectiveness
Conditions Merger Conference Call
Conference Call Scheduled 800 Conference Call Scheduled 830
Conference Call Scheduled 845 Conference Call Scheduled 900 Est
Conference Call Webcast Information Consent Independent Registered Public Accounting Firm
Consolidated Financial Statements Consolidated Statements Other Financial Information
Consolidation Merger Sale Conveyance Contacts
Contingencies Continuing Directors
Controls Procedures Convertible Debentures
Convertible Senior Debentures Convertible Senior Debentures Due 2026
Cooperation Agreements Copaxone
Copaxone Reg Copaxone Reg Approved Fda Patients Clinical Event Suggestive
Copaxone Reg Clinical Studies Copaxone Reg Glatiramer Acetate Injection
Copaxone Reg Significantly Reduced Annual Relapse Rates Stabilized Copaxonereg
Copaxonereg Significantly Decreases Disease Activity Patients Switched Interferon Corey Davis -natixis Securities-analyst
Corey Davis Natixis Securities Analyst Corporate Governance Nominating Committee
Corporate Secretary Corporate Tax Rate
Counterparts Court Appeals Affirms Teva`s Generic Zocorreg Exclusivity
Court Appeals Rules Favor Teva Biaxinreg Preliminary Injunction Court Grants Stay Fda Approval Until After Close
Court Grants Teva Summary Judgment Non-infringement Eloxatinreg Critical Accounting Policies
Current Economic Conditions Adversely Affect Industry Business Results Current Members Board Committees
Czech Republic Data Longest Continuous Study Treatment Presented European Committee
David Buck -buckingham Research Group-analyst David Buck Buckingham Research Analyst
Debt Deferred Income Taxes
Definite Life Intangible Assets Definitions
Derivative Instruments Hedging Activities Derivatives
Description Teva Ordinary Shares Diluted Earnings Per Share
Directors Directors Being Considered Election Annual Meeting
Directors Powers Directors Senior Management
Directors Subject Reelection Distribution Stock Dividend
District Court Grants Teva Summary Judgment Generic Zocorreg Divestitures
Dividend Dividends
Documents Display Doubled Dose Copaxone Reg Maintained Proven Safety Profile
Doubling Dose Copaxonereg Further Reduced Relapses Lesions E-mail Teltslawcoil
Earnings Guidance Earnings Loss Per American Depository Receipt Adr
Earnings Loss Per Share Earnings Per Adr
Earnings Per American Depository Receipt Adr Earnings Per Share
Ecitals Economic Environment
Edmund Kim -jpmorgan Chase Co-analyst Edratide
Efficacy Attained Study Stopped After Interim Analysis Supports Elect Sell Generic Product Prior Court Decision Completion
Elect Sell Generic Product Prior Final Resolution Outstanding Eligibility
Employee Related Obligations Consisted Following Employee Stock Option Plans
Employee Stock-based Plans Employees
Entry Material Definitive Agreement Environmental
Environmental Matters Estimates Preparation Financial Statements
Europe Event Subsequent 2005-acquisition Ivax Corporation
Event Subsequent 2007 Acquisition Cogenesys Inc Event Subsequent 2008-sale Animal Health
Events Default Exact Name Registrant Specified Charter
Except Per Share Data Organization Exchange Rate
Exchange Rate Risk Management Executive Officers
Exhibits Expenses
Expenses Connection Collaboration Agreements Expenses Solicitation Proxies
Experience Difficulties Integrating Ivaxs Business Existing Businesses Explanatory Notes
Exploiting Exclusivity Periods Potential Liability Sales Generic Products Extended Storage Provides Enhanced Convenience Relapsing-remitting Multiple Sclerosis
Eyal Desheh Teva Pharmaceutical Cfo Failure Comply Applicable Environmental Laws Regulations Worldwide Adversely
Fair Value Measurement Fas 151
Fas 154 Fas 155
Federal Circuit Affirms Denial Preliminary Injunction Regarding Teva`s Federal Income Tax Considerations
Federal Trade Clears Teva Ivax Merger Closing Scheduled Fen-phen Litigation
Filing Marketing Authorization Europe Expected 2010 Finance Committee
Financial Data Financial Expenses
Financial Expenses Income Financial Expenses Net
Financial Guidance 2006 Raised Financial Income
Financial Income Expenses Financial Income Expenses -net
Financial Instruments Risk Management Financial Outlook
Financial Statement Schedule Financial Statements
Financial Statements Exhibits Foreign Exchange Regulations
Form 20-f Form 6-k
Form Guarantee Forward-looking Statement Whether Result New Information Future Events
Forward-looking Statements France
Frank Pinkerton -banc America-analyst Functional Currency
General General Administrative
General Administrative Expenses Generic Pharmaceutical Products Face Intense Competition Brand-name Companies
Generic Prevacidreg Solutab Generic Products
Generics Geographical Information
Gerard Van Odijk -teva Pharmaceutical Europe-president Ceo Gerard Van Odijk Teva Europe President Ceo
Germany Glatiramer Acetate
Global Branded Products Global Branded Products Group
Goal Reach Sales 2015 Goodwill
Goodwill Indefinite Life Intangible Assets Goodwill Intangible Assets Debt Issuance Costs
Governing Law Place Jurisdiction Gprd
Greement Greement Lan Erger
Gregg Gilbert -merrill Lynch-analyst Gross Profit
Gross Profit Margin Gross Research Development Expenses Reached 102 Sales Grew
Guarantee Hapoalim Loan
Highlights Hold Conference Call 845 Eastern Time
Holder Federal Income Tax Purposes Hospitals Institutional Channels
Hospitals Institutional Channels Teva Supported Global Supply System Host Marketsite Event 2007
Householding Proxy Materials Householding Proxy Materials Electronic Delivery
Hungary Immediate Release
Immeidate Release Impact Currency Fluctuations
Impact Currency Fluctuations Inflation Impairment Purinethol Product Rights
Impairment Restructuring Expenses Impairment Value Long-lived Assets
Impairment Value Long-lived Assets Definite Life Intangible Important Information
Important Safety Information Important Safety Information Tev-tropinreg
In-process Research Development Iprd Income
Income Before Taxes Composed Following Income Taxes
Income Taxes Non-israeli Subsidiaries Increases Equity Stake Hualida Biotechnology
Increasing Amount Intangible Assets Goodwill Books Lead Significant Indemnity
Independent Registered Public Accounting Firm Fees Index
Index Consolidated Financial Statements Index Financial Statements
Indicate Number Outstanding Shares Each Issuer Classes Capital Induction Regime Reduced Mri-measured Disease Activity Was Sustained
Information Reporting Backup Withholding Initiation Enrollment Pivotal Phase Clinical Study Oral Laquinimod
Innovative Products Innovative Projects
Innovative Specialty Products Intangible Assets
Intangible Assets Debt Issuance Costs Intellectual Property Other Protections
Intellectual Property Proceedings Intended Facilitate Investors` Analysis Results
Internal Control Over Financial Reporting International
Interpretation Introduction
Introduction Certain Terms Inventories
Investee Companies Investments Advances Unconsolidated Affiliates
Israel Israel Other Countries
Israeli Operations Adversely Affected Recent Hostilities Involving Israel Israeli Subsidiaries
Israeli Veterinary Business Issuance Convertible Senior Debentures
Issuance Senior Notes Ist Xhibits
Italy Ivax
Ivax Acquisition Ivax Convertible Notes
Ivax Integration Activities Ivax Recent Developments
Ivax` Convertible Senior Notes Due 2025 Jerusalem Israel 2008
Jerusalem Israel 2009 Jerusalem Israel Scottsdale Arizona 8211 2009
Jerusalem Plant Fda Inspection Future Impact Ken Cacciatore -sg Cowen-analyst
Ken Cacciatore Cowen Analyst King Pharmaceuticals
Known Trends Kowa
Kowa Cooperation Agreement Ladostigil Tartrate Tv-3326 Novel Compound Developed Treatment Alzheimers
Laquinimod Laquinimod Novel Oral Compound Showed Significant Reduction Disease
Largest Parkinson`s Disease Studies Demonstrates Benefit Early Treatment Latin America
Law Encouragement Capital Investments 1959 Investment Law Encouragement Industry Taxes 1969
Lawyers Confirmation Leading Multiple Sclerosis Therapy Presents Significant Legal Regulatory
Legal Counsel Confirmation Legal Proceedings
Legal Settlements Impairment Restructuring Letter Undertaking
Leumi Loan Liat Hayardeny Sara Feigelson Valentin Grabovsky Joel Kaye
Liquidity Capital Resources Litigation Settlement Impairment Restructuring Expenses
Loans Payable Long-lived Assets
Long-term Employee-related Obligations Long-term Employee-related Obligations Consisted Following
Long-term Loans Other Liabilities Long-term Loans Other Liabilities Consisted Following
Lonza Lonza Cooperation Agreement
Lundbeck Major Shareholders Related Party Transactions
Management Considers Appropriate Adjustment Manufacture Products Highly Complex Sometimes Single-sourced Supply Interruption
Marc Goodman -credit Suisse-analyst Margin
Market-leading Multiple Sclerosis Therapy Presents Significant Legal Regulatory Marketable Securities
Marketing Sales Material Changes Contractual Obligations
Matters Involving Barr Pharmaceuticals Inc Subsidiaries Measurement Results Israeli Tax Purposes
Measurement Results Tax Purposes Mediwounds Debrasereg
Meeting Meetings Shareholders
Merger Merger Agreement
Merger Etc Guarantor Mergers Acquisitions
Michael Tong -wachovia Securities-analyst Miscellaneous Provisions
Miscellaneous Regulatory Matters Multiple Sclerosis
Name Telephone E-mail Facsimile Number Address Contact Person Nature Guarantee
Nature Termination Guarantee Negative Covenants
Net Income Net Income Earnings Per Adr
Net Income Earnings Per Share Net Income Loss
Net Income Share Count Net Research Development
Net Sales Netherlands
Neurology Pipeline Neutropenia
New Data Copaxone Reg Combination Presented Late-breaking News New Data Illustrate Novel Mechanism Action Laquinimod Oral
New Patient-friendly Option Available Tev-tropin-- New Ventures
Nominating Committee Non-infringement Gabapentin
Non-israeli Subsidiaries Nora Tarcic Emanuel Raymond Joel Kaye Netanya Israel
North America Northern Ireland Department Health Social Services Public Safety
Not Able Consummate Integrate Future Acquisitions Not Able Successfully Identify Consummate Integrate Future Acquisitions
Not Achieve Revenue Cost Synergies Anticipated Combined Not Applicable
Notes Condensed Consolidated Financial Statements Basis Presentation Notes Pro Forma Combined Condensed Financial Statements
Notice Notice Annual Meeting Shareholders
Notice Regard Tevas Annual Shareholders Meeting Nomination Joseph Notice Special Meeting Shareholders
Notice Withdrawal Notices
Now Therefore Request Hereby Confirm Declare Undertake Towards Nternational Pharmaceutical Sales
Number Ordinary Shares Issuable Exercise Options Outstanding Number Ordinary Shares Issuable Exercise Options Vested
Off-balance Sheet Arrangements Once-daily Novel Oral Agent Relapsing Remitting Multiple Sclerosis
Oncology Emerging Therapeutics Pipeline Oncology Pipeline
One-time Included 2004 One-time Included Half 2004
Operating Financial Review Prospects Operating Income
Operations Operations Selected Cee Countries
Operations Selected European Countries Operations Selected Latin American Countries
Oral Copaxone Oral Laquinimod Multiple Sclerosis Granted Fast Track Status
Ordinary Shares Organization
Organizational Structure Other Countries
Other Countries Tevas International Group Other Events
Other Innovative Projects Other Key Financial Data Events
Other Litigation Other Projects
Other Recently Adopted Accounting Pronouncements Other Recently Issued Accounting Pronouncements
Other Sales Parkinson`s Disease
Parkinsons Disease Part
Participation Grant Exercise Option Payroll Deductions Delivery Adrs Parties Also Agree Business Arrangements Related Modafinil
Patent Litigation Patent Litigation Settlement Agreements Important Business Facing Increased
Patient Undergoes Expanded Cord Blood Transplant Excell Registration Patients Now Being Enrolled Gamida Cell-teva Joint Venture
Pediatric Asthma Performance Guidance
Persons Being Considered Election Annual Meeting Petach Tikva 49131 Israel
Pharmaceutical Production Pharmaceutical Sales
Pharmaceutical Sales Europe Pharmaceutical Sales North America
Pharmaceutical Susceptible Product Liability Claims Not Covered Insurance Phase Laquinimod Trials
Phase Program Phase Study Design Results
Phil Frost Teva Pharmaceutical Vice Chairman Plan Reg -step Intended Prevent Pregnancy After Known
Plan Reg One-step Planned Merger
Poland Poland 2006 Teva Rationalized Generic Product Portfolio Registered
Policy Pre-approval Audit Non-audit Services Independent Auditors Policy Pre-approval Audit Non-audit Services Independent Registered Public
Political Instability Foreign Currency Fluctuations Restrictions Adversely Affect Pravastatin
Precise Study Preliminary
Preparations Underway Commence Phase Study Presentation 2008 Financial Statements
President Ceo Announces Retirement President Chief Executive Officer
Prevacidreg Delayed-release Capsules Principal Accountant Fees Services
Principles Consolidation Pro Forma Combined Condensed Financial Statements
Proair Reg Hfa Registered Trademark Teva Specialty Pharmaceuticals Procognia Israel Ltd
Product Liability Matters Product Rights
Production Promissory
Properties Facilities Property Plant Equipment
Property Plant Equipment-by Geographical Location Proposal Amendment Company`s Articles Association
Proposal Appointment Independent Registered Public Accounting Firm Proposal Appointment Statutory Independent Director
Proposal Approval 2005 Dividend Proposal Approval 2006 Dividend
Proposal Approval 2008 Dividend Proposal Approval 2008 Employee Stock Purchase Plan Employees
Proposal Approval Increase Directors Cash Remuneration Proposal Approval Increase Directors` Remuneration
Proposal Approval Liability Insurance Directors Proposal Approval Liability Insurance Directors Officers
Proposal Approval Remuneration Frost Proposal Approval Remuneration Hurvitz
Proposal Election Directors Proposal Presentation Financial Statements
Proposals Proposed New Directors
Proprietary Products Protalix
Purchases Equity Securities Issuer Affiliated Purchasers Pursuant Rule 13a-16 15d-16 Securities Exchange Act 1934
Quantitative Qualitative Disclosures Market Risk Question Answer
Questions Answers Quorum Majority Required Resolution
Quorum Required Vote Voting Procedures Quorum Voting Procedure
Randall Stanicky -goldman Sachs-analyst Randall Stanicky Goldman Sachs Analyst
Raw Materials Pharmaceutical Production Real Life Study Shows Effectiveness Qvar Reg Beclomethasone-cfc
Realization Units Viventia Biotech Recent Accounting Pronouncements
Recently Adopted Accounting Pronouncement Recently Adopted Accounting Pronouncements
Recently Adopted Accounting Standard Recently Issued Accounting Pronouncement
Recently Issued Accounting Pronouncements Recently Issued Accounting Standards
Recently Proposed Accounting Pronouncement Reclassifications
Reconciliation Between Reported Adjusted Net Income Reconciliation Between Reported Adjusted Net Income Loss
Reconciliation Between Reported Gaap Income Earnings Per Adr Reconciliation Between Reported Gaap Income Loss Earnings Per
Reconciliation Between Reported Income Earnings Per Share Adjusted Reconciliation Between Reported Income Loss Earnings Per Share
Reconciliation Between Reported Net Income Attributable Teva Earnings Reconciliation Between Reported Net Income Earnings Per Share
Reconciliation Between Reported Net Income Loss Earnings Per Reconciliation Between Reported Normalized Net Income Loss
Record Date Shareholders Entitled Vote Recruitment Still Ongoing Pivotal Phase Study Bravo
Redemption Debentures Redemption Securities
Reducing Medication Food Restrictions Reforms Health Care Industry Uncertainty Associated Pharmaceutical Pricing
Reforms Healthcare Industry Uncertainty Associated Pharmaceutical Pricing Reimbursement Registered Offerings
Regulations Permit Sale Biotechnology-based Products Bioequivalent Biosimilar Drugs Relapsing-remitting Multiple Sclerosis Patients Experience Significantly Extended Time
Related Party Transactions Release Guarantee
Remainder Page Intentionally Left Blank Report Independent Registered Public Accounting Firm
Report Independent Registered Public Accounting Firm Financial Statement Representations Warranties
Representations Warranties Buyer Acquisition Sub Repurchase Option Holder
Research Development Research Development Efforts Invested Innovative Pipeline Not Achieve
Research Development Expenses Research Development In-process Iprd
Research Development Patents Licenses Respiratory
Respiratory Collaboration Agreement Respiratory Products
Rest World Restructuring Expenses
Results Include Ivax Time Results Operations
Results Presented Congress European Federation Neurological Societies Retained Earnings
Retirement Plans Revenue Recognition
Revenues Cost Sales Revenues Profits Closely Tied Success Obtaining Market Exclusivity
Revenues Profits Generic Pharmaceutical Products Decline Result Intense Revenues Profits Generic Pharmaceutical Products Generally Decline Competitors
Revenues Profits Particular Generic Pharmaceutical Product Decline Competitors Revenues Profits Particular Generic Pharmaceutical Products Decline Competitors
Revise Forward-looking Statement Whether Result New Information Future Rich Silver Lehman Brothers Analyst
Ricky Goldwasser -ubs-analyst Right Non-israeli Shareholders Vote
Risk Factors Rotem Or-bach Polina Sonis Michael Gurevich Anat Achiron
Safe Harbor Statement Private Securities Litigation Reform Act Sale Product Rights
Sales Active Pharmaceutical Ingredients Api Sales Business Segment
Sales Business Segments Sales Copaxone Adversely Affected Competition
Sales General Sales Geographical Area
Sales Geographical Areas Sales Innovative Products Especially Copaxone Adversely Affected Competition
Sales Last Crossed Dollar Sales Products Adversely Affected Continuing Consolidation Distribution Network
Sales Products Adversely Affected Continuing Recent Consolidation Distribution Sanofi Aventis Forward Looking Statements
Sanofi-aventis Sanofi-aventis Teva
Sarbanes-oxley Act 2002 Satisfaction Discharge
Science Technology Committee Secures Sufficient Cash On-hand Complete Transaction
Securities Exchange Act 1934 Securities Registered Pursuant Act
Securities Reporting Obligation Pursuant Act Securities Repurchase Program
Securities Set-off Application Payments See
See Reconciliation Attached Selected Financial Data
Selling General Administrative Expenses Selling General Administrative Expenses Sga
Selling General Administrative Sga Selling General Administrative Sga Expenses
Selling Markeing Selling Marketing
Selling Marketing Expenses Senior Notes Loans
Shall Governed Construed Accordance Law State New York Share Capital
Share Count Share Ownership
Share Repurchases Shareholder Nominations
Shareholders Equity Shareholders` Meeting
Shares Held Subsidiaries Shipping Handling Costs
Shlomo Yana -teva Pharmaceutical-president Ceo Shlomo Yanai
Shlomo Yanai Succeed President Ceo Shlomo Yanai Teva8217s President Chief Executive Officer
Short Term Debt Short-term Credit
Sicor Acquisition Signature
Signatures Significant Changes Respect Financial Statements Teva Barr Combined
Significant Cooperation Agreements Significant Future Factors Performance Guidance
Significant International Operations Including Israel Adversely Affected Acts Significant Operations Countries Adversely Affected Acts Terrorism Political
Significantly Strengthens Tevas Market Leadership Position Key Global Sold Elect Sell Future Generic Products Prior Final
Spain Special Meeting
Specialty Pharmaceutical Products Specialty Products
Status Non-vested Rsus Statutory Independent Directors
Statutory Independent Directors Financial Expertise Statutory Independent Directors Financial Experts
Stock Based Compensation Stock Repurchase Program
Stock-based Compensation Stockholders Equity
Strategy Strengthens Global Leadership Generics Adds New Product Lines
Studies Study
Study Confirm Phase Results Showing Reduced Relapses Lesions Study Design Results
Study Showed Significant Sustained Efficacy Copaxone Reg Alone Subject Government Regulation Increases Costs Prevent Marketing Selling
Submission Jurisdiction Submission Matters Vote Security Holders
Subpart 214 Financial Covenants 710 Existing Credit Agreement Subpart 216 Financial Covenants 710 Existing Credit Agreement
Subscription Agreement Subsequent Event
Subsequent Events Success Depends Ability Successfully Develop Commercialize Additional Pharmaceutical
Success Depends Ability Successfully Develop Commercialize Pharmaceutical Products Success Innovative Products Depends Effectiveness Patents Confidentiality Agreements
Success Innovative Products Depends Effectiveness Patents Other Measures Supplemental Adjusted Income Data
Supplemental Disclosure Cash Flow Information Supplemental Disclosure Non Cash Investing Financing Activities
Supplemental Disclosure Non-cash Financing Activities Supplemental Disclosure Non-cash Investing Financing Activities
Supplemental Indentures Supplemental Non-gaap Income Data
Supplementary Disclosure Non-cash Financing Activities Surviving Corporation
Susceptible Product Liability Claims Not Covered Insurance Susceptible Product Liability Claims Not Covered Insurance Including
Table Contents Tablets
Tal Birnberg Steffen Jung Rehovot Israel Tax
Tax Assessments Tax Benefits Israeli Law Encouragement Capital Investments 1959
Tax Benefits Israeli Law Encouragement Industry Taxes 1969 Tax Rate
Tax Rates Israel Applicable Income Other Sources Tax Reform Legislation
Taxation Disposition Adrs Taxation Disposition Adss
Taxation Distributions Taxation Dividends
Taxation Non-israeli Subsidiaries Taxes
Terazosin Litigation Term
Termination Termination Agreements
Termination Amendment Waiver Termination Expiration Governmental Programs Tax Benefits Adversely Affect
Terms Arrangements Tev-tropinreg
Teva Teva Active Biotech Announce Laquinimod Phase Data Been
Teva Active Biotech Announce Submission Ind Fda Laquinimod Teva Active Biotech Initiate Pivotal Phase Trial Program
Teva Announces Agreement Allegrareg Patent Challenge Teva Announces Agreement Generic Pulmicort Respulesreg Patent Challenge
Teva Announces Agreement Pfizer Regarding Idarubicin Azithromycin Epirubicin Teva Announces Amir Elstein Joins Board Directors
Teva Announces Appeals Court Ruling Affirming Invalidation Yasminreg Teva Announces Appellate Court Reverses Generic Risperdalreg Exclusivity
Teva Announces Approval Alprazolam Tablets Teva Announces Approval Amoxicillin Clavulanate Potassium Chewable Tablets
Teva Announces Approval Azithromycin Tablets Teva Announces Approval Cefprozil Tablets Oral Suspension Usp
Teva Announces Approval Clozapine Tablets 100 Teva Announces Approval Deferoxamine Mesylate Injection Usp
Teva Announces Approval Desmopressin Acetate Tablets Teva Announces Approval Fluconazole Injection
Teva Announces Approval Generic Camptosarreg Teva Announces Approval Generic Flolanreg Injection
Teva Announces Approval Generic Kytrilreg Injection Tablets Teva Announces Approval Generic Lexaproreg Tablets
Teva Announces Approval Generic Risperdal Reg Oral Solution Teva Announces Approval Generic Yazreg Tablets
Teva Announces Approval Glimepiride Tablets Teva Announces Approval Glipizide Metformin Hcl Tablets
Teva Announces Approval Glyburide Metformin Hcl Tablets Teva Announces Approval Launch Generic Urso 250reg Fortereg
Teva Announces Approval Launch Oxaliplatin Injection Teva Announces Approval Launch Tri-lo Sprintec Tablets
Teva Announces Approval Leflunomide Tablets Teva Announces Approval Metformin Hcl Extended Release Tablets
Teva Announces Approval Methylprednisolone Acetate Injectable Suspension Teva Announces Approval Mitoxantrone Hydrochloride Injection Usp
Teva Announces Approval Ondansetron Injection Usp Teva Announces Approval Paroxetine Hcl Tablets
Teva Announces Approval Polyethylene Glycol 3350 Oral Solution Teva Announces Approval Pravastatin Sodium Tablets
Teva Announces Approval Rabeprazole Sodium Delayed-release Tablets Teva Announces Approval Shipment Generic Omnicefreg Capsules Pos
Teva Announces Azilectreg Rasagiline Approved Marketing Israel Teva Announces Brussels Court Decision Revoke Msds European
Teva Announces Closing Cogenesys Acquisition Teva Announces Court Appeals Grants Favorable Ruling Once-a-week
Teva Announces Court Decisions Revoke Msds European Patent Teva Announces Extension Patent Protection Azilectreg
Teva Announces Extension Standstill Agreement Generic Protonixreg Teva Announces Favorable Court Decision Regarding Generic Allegra
Teva Announces Fda Determination Generic Pravachol Exclusivity Not Teva Announces Fda Grants Approval Azilect Reg Rasagiline
Teva Announces Final Approval Meloxicam Tablets Teva Announces Final Approval Mirtazapine Orally Disintegrating Tablets
Teva Announces Final Approval Oxycodone Tablets Teva Announces Final Approval Ribavirin Tablets
Teva Announces Final Results Merger Consideration Connection Ivax Teva Announces Ftc Not Objections Effexorreg Settlement
Teva Announces Global In-market Sales Blockbuster Copaxone Reg Teva Announces Global In-market Sales Copaxone Reg Increased
Teva Announces Global In-market Sales Copaxonereg Increased 542 Teva Announces Launch Generic Wellbutrin Xlreg Tablets 150
Teva Announces Offering 275 Senior Notes Convertible Debentures Teva Announces Oxycontin Reg Litigation Dismissed Settlement Purdue
Teva Announces Planned Retirement Cfo Dan Suesskind Mid-2008 Teva Announces Pricing 125 Convertible Debentures
Teva Announces Sale Israeli Veterinary Business Phibro Animal Teva Announces Settlement Agreement Regarding Auction Rate Securities
Teva Announces Settlement Lamictalreg Litigation Glaxosmithkline Teva Announces Stay Approval Generic Pravachol Lifted
Teva Announces Submission Biologics License Application Bla Xm02 Teva Announces Tentative Approval Adenosine Injection
Teva Announces Tentative Approval Amlodipine Besylate Tablets Teva Announces Tentative Approval Divalproex Sodium Delayed-release Tablets
Teva Announces Tentative Approval Fexofenadine Hcl Tablets Teva Announces Tentative Approval Gatifloxacin Tablets
Teva Announces Tentative Approval Generic Ariceptreg Tablets Teva Announces Tentative Approval Generic Cozaar Reg Tablets
Teva Announces Tentative Approval Generic Diovanreg Tablets Teva Announces Tentative Approval Generic Flomaxreg Capsules
Teva Announces Tentative Approval Generic Gemzarreg Injection Teva Announces Tentative Approval Generic Prevacidreg Delayed-release Capsules
Teva Announces Tentative Approval Generic Risperdalreg Oral Solution Teva Announces Tentative Approval Granisetron Hydrochloride Injection
Teva Announces Tentative Approval Levofloxacin Injection Teva Announces Tentative Approval Losartan Potassium Hydrochlorothiazide Tablets
Teva Announces Tentative Approval Octreotide Acetate Injection Teva Announces Tentative Approval Olanzapine Tablets
Teva Announces Tentative Approval Ondansetron Injection Usp Teva Announces Tentative Approval Rabeprazole Sodium Delayed-release Tablets
Teva Announces Tentative Approval Risedronate Sodium Tablets Teva Announces Tentative Approval Simvastatin Tablets
Teva Announces Tentative Approval Simvastatin Tablets Provides Update Teva Announces Tentative Approval Sumatriptan Succinate Tablets
Teva Announces Tentative Approval Topiramate Tablets Teva Announces Tentative Approval Tramadol Acetaminophen Tablets
Teva Announces Tentative Approval Zaleplon Capsules Teva Announces Wyeth Voids Standstill Agreement Generic Protonixreg
Teva Barr Announce Launch Generic Allegra Reg Tablets Teva Barr Invites Public Listen Webcast
Teva Barr Provide Update Acquisition Teva Comments Clarithromycin Tablet Litigation
Teva Comments Fda Letter Regarding Pravastatin Exclusivity Teva Comments Market Rumors
Teva Comments Pfizer Press Release Regarding Azithromycin Teva Completes Acquisition Bentley Pharmaceuticals
Teva Completes Enrollment Laquinimod Phase Clinical Trial Teva Completes Enrollment Oral Laquinimod Phase Clinical Trial
Teva Draws Down Recently Established 350 Syndicated Loan Teva Explore Strategic Alternatives Animal Health Business
Teva Host Conference Call Professor Warren Olanow Teva Innovative Ventures
Teva Intends Conduct Additional Pre-clinical Clinical Research Before Teva Introduces Fexofenadine Hcl Pseudoephedrine Extended-release Tablets Alternative
Teva Introduces Generic Adderall Xrreg Capsules United States Teva Invites Public Listen Investor Webcast
Teva Ivax Announce Ftc Review Process Continues Track Teva Ivax Cash Stock Election Deadline Update
Teva Ivax Receive European Approval Acquisition Teva Ivax Shareholders Approve Pending Merger
Teva Ivax Sign Consent Order Schedule Anticipated Closing Teva Lonza Announce Strategic Partnership Become Leading Global
Teva Lundbeck Announce European Approval Azilectreg Rasagiline 1mg Teva Neuroscience
Teva Ortho-mcneil-janssen Settle Ortho Tri-cyclenreg Litigation Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Limited Teva Pharmaceutical Industries Ltd
Teva Pharmaceutical Industries Ltd Web Site Wwwtevapharmcom Teva Present 2008 Wachovia Healthcare Conference
Teva Present 2nd Annual Nasdaq Tase Israeli Investor Teva Present Bank America Health Care Conference
Teva Present Bear Stearns Annual London Healthcare Conference Teva Present Goldman Sachs Annual Global Healthcare Conference
Teva Present Lehman Brothers 11th Annual Global Healthcare Teva Present Morgan Stanley Pharmaceutical Ceos Unplugged Conference
Teva Present New Data Innovative Therapies Multiple Sclerosis Teva Present Piper Jaffray Annual Europe Conference
Teva Present Ubs Global Life Sciences Conference Teva Present Ubs Global Specialty Generic Pharmaceuticals Conference
Teva Proair Reg Hfa Market Leading Albuterol Inhaler Teva Procognia Israel Ltd Sign Exclusive Collaboration Agreement
Teva Provid Update Generic Singulairreg Litigation Teva Provides 2008 2009 Financial Outlook
Teva Provides Generic Biaxin Reg Update Teva Provides Update Generic Actonelreg Litigation
Teva Provides Update Generic Ariceptreg Litigation Teva Provides Update Generic Celebrexreg Litigation
Teva Provides Update Generic Evista Reg Litigation Teva Provides Update Generic Ortho Tri-cyclenreg
Teva Provides Update Generic Pravachol Exclusivity Teva Provides Update Generic Pravacholreg
Teva Provides Update Generic Prevacid Reg Litigation Teva Provides Update Generic Prevacidreg Litigation
Teva Provides Update Generic Protonixreg Teva Provides Update Generic Pulmicort Respulesreg Launch
Teva Provides Update Generic Risperdalreg Teva Provides Update Generic Seroquel Reg Litigation
Teva Receives Approval Generic Dostinexreg Tablets Teva Receives Approval Generic Pulmicort Respules Commences Commercial
Teva Receives Approval Generic Risperdalreg Tablets Commences Commercial Teva Receives Approval Generic Unireticreg Tablets
Teva Receives Court Ruling Awarding Exclusivity Generic Risperdalreg Teva Receives Favorable Court Ruling Generic Pravacholreg Exclusivity
Teva Receives Favorable Ruling Japanese Patent Office Regarding Teva Receives Fda Approval Generic Proscarreg Tablets
Teva Receives Fda Approval Generic Zoloft Reg Tablets Teva Receives Positive Results Aok Tender
Teva Receives Tentative Approval Generic Protonixreg Delayed Release Teva Recommends Rejection Mini-tender Offer Trc Capital
Teva Reports 2005 Results Teva Reports 2007 Results
Teva Reports Record Sales Net Income Full 2005 Teva Savient Launch Tev-tropin Pediatric Growth Hormone Deficiency
Teva Sell Oxycodone Through End 2007 Teva Shares Adrs
Teva Updates 2008 Financial Outlook Teva Work Fda Modify Azilectreg Label
Teva Wyeth Announce Settlement Effexor Xrreg Litigation Teva-kowa Pharma Joint Venture
Teva`s Developed G-csf Biosimilar Receive Positive Opinion European Teva`s Safe Harbor Statement Private Securities Litigation Reform
Tevas Safe Harbor Statement Private Securities Litigation Reform Tim Chiang -ftn Midwest Research-analyst
Title Class Transaction Extends Teva`s Leadership Key Global Markets Strengthens
Transaction Terms Treasury Shares
Treatment Laquinimod Reduces Development Active Mri Lesions Trend Information
Tulchinsky-stern Law Offices Tyramine Study
Ucb Ucb Forward-looking Statement
Unidentified Representative United Kingdom
United Kingdom Serious Fraud Office Investigation Related Litigation United States
University Hospitals Updated Label Offers Early Treatment Copaxonereg
Validity Guarantee Valrocimide
Venlafaxine Very Active Multiple Sclerosis Patients Benefited Copaxone Reg
Voting Agreement Voting Way Card
Waivers Amendments Was Safe Well Tolerated Als Patients However Study
Webcast Webcast Alert -for Immediate Release
Webcast Alert Immediate Release Website Wwwtevapharmcom
William Marth President Ceo Teva North America Withholding Taxes Dividends Distributed Teva Non-israeli Residents
Women8217s Health Womens Health
Wwwtevapharmcom Wwwtevapharmcom Wwwbarrlabscom
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki